VEGFA and hepatocellular carcinoma: Sorafenib is a molecular-targeted drug for HCC that inhibits angiogenesis through receptors for vascular endothelial growth factor (VEGF) or platelet-derived growth factor and by suppressing tumor cell proliferation through the Raf-mediated pathway and receptor tyrosine kinases [4].